La bourse ferme dans 6 h 27 min

Vertex Pharmaceuticals Incorporated (VRTX)

NasdaqGS - NasdaqGS Cours en temps réel. Devise en USD
Ajouter à la liste dynamique
234,06+7,48 (+3,30 %)
À la clôture : 04:00PM EST
233,68 -0,38 (-0,16 %)
Échanges après Bourse : 07:42PM EST

Vertex Pharmaceuticals Incorporated

50 Northern Avenue
Boston, MA 02210
United States
617 341 6100
https://www.vrtx.com

Secteur(s)Healthcare
Secteur d’activitéBiotechnology
Employés à temps plein3 400

Dirigeants clés

NomTitrePayerExercéAnnée de naissance
Dr. Jeffrey Marc Leiden M.D., Ph.D.Exec. Chairman3,14M36,36M1956
Dr. Reshma Kewalramani FASN, M.D.CEO, Pres & Director3,86M506,93k1973
Mr. Charles F. Wagner Jr.Exec. VP & CFO1,71MS.O.1968
Mr. Stuart A. Arbuckle B.Sc.Exec. VP & COO2,03M2,07M1966
Dr. David M. AltshulerExec. VP of Global Research & Chief Scientific Officer1,81M2,03M1965
Ms. Kristen AmbroseChief Accounting Officer & SVP of Accounting, Tax, Treasury, Strategic Sourcing & Corp. ServicesS.O.S.O.1976
Mr. Mike TirozziSVP and Chief Information & Data OfficerS.O.S.O.S.O.
Mr. Michael PartridgeSr. VP of Investor RelationsS.O.S.O.S.O.
Mr. Damian W. Wilmot Esq.Sr. VP, Chief Risk and Compliance OfficerS.O.S.O.1976
Ms. Joy LiuSr. VP & Gen. CounselS.O.S.O.S.O.
Les montants ont été établis en date du 31 décembre 2020 et les valeurs de compensation concernent le dernier exercice fiscal clos à cette date. Le terme « rémunération » désigne le salaire, les bonus, etc. Le terme « exercé » est utilisé pour la valeur des options exercées au cours de l’exercice fiscal. Devise exprimée en USD.

Description

Vertex Pharmaceuticals Incorporated engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 12 years of age or older who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator, or CFTR, gene. Its pipeline includes Pipeline for Alpha-1 antitrypsin deficiency that is in Phase 2 clinical trial; VX-864, a second investigational small molecule corrector for the treatment of AAT deficiency, which is in Phase 1 clinical trial; and VX-147 that completed a Phase 1 clinical trial for the treatment of APOL1-mediated focal segmental glomerulosclerosis, or FSGS, and other serious kidney diseases. The company sells its products primarily to specialty pharmacy and specialty distributors in the United States, as well as specialty distributors and retail chains, and hospitals and clinics internationally. Vertex Pharmaceuticals Incorporated has collaborations with CRISPR Therapeutics AG; Arbor Biotechnologies, Inc.; Moderna, Inc.; Genomics plc; Merck KGaA; Darmstadt, Germany; X-Chem, Inc.; Janssen Pharmaceuticals, Inc.; Merck KGaA; Kymera Therapeutics; Ribometrix, Inc.; Molecular Templates, Inc.; Mammoth Biosciences; and Affinia Therapeutics, as well as a strategic research collaboration and licensing agreement with Obsidian Therapeutics, Inc. for the discovery of novel therapies that regulate gene editing for the treatment of serious diseases. The company was founded in 1989 and is headquartered in Boston, Massachusetts.

Gouvernance d’entreprise

L’ISS Governance QualityScore de Vertex Pharmaceuticals Incorporated en date du 26 septembre 2021 est 7. Les scores principaux sont Audit : 7; Société : 7; Droits des actionnaires : 6; Compensation : 7.

Résultats de gouvernance d’entreprise offerts par Institutional Shareholder Services (ISS). Les résultats indiquent un rang décile par rapport à l’indice ou à la région. Un résultat décile de 1 indique un risque de gouvernance faible, tandis que 10 indique un risque de gouvernance élevé.